Community Investing Ideas

Global Weekly Picks

US$21.53
FV
60.2% undervalued intrinsic discount
7.2k
users have viewed this narrative
19users have liked this narrative
0users have commented on this narrative
136users have followed this narrative
US$42.3
FV
13.7% undervalued intrinsic discount
2.9k
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
US$989.24
FV
51.0% undervalued intrinsic discount
19.96%
Revenue growth p.a.
2.4k
users have viewed this narrative
1users have liked this narrative
2users have commented on this narrative
32users have followed this narrative
US$190.78
306.8% overvalued intrinsic discount
Fair Value
Revenue
7% p.a.
Profit Margin
22.85%
Future PE
30.78x
Price in 2030
US$316.47
CRMD logo
CorMedix

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events

Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Read more

View narrative
US$12
33.9% undervalued intrinsic discount
Fair Value
Revenue
38.8% p.a.
Profit Margin
51.99%
Future PE
3.42x
Price in 2031
US$16.82
ر.س15.04
0.4% undervalued intrinsic discount
Fair Value
Revenue
22.13% p.a.
Profit Margin
9.24%
Future PE
15.5x
Price in 2031
ر.س38.09
US$274.31
63.9% overvalued intrinsic discount
Fair Value
Revenue
30% p.a.
Profit Margin
15%
Future PE
60x
Price in 2028
US$360.63
BRC logo
Blackrock Silver

Nevada 1st-Tier 30 Baggers Silver Play Potential

🪙 Blackrock Silver Corp. (TSXV: BRC) Blackrock Silver is a high-grade silver–gold developer/explorer advancing Tonopah West in Nevada.Read more

View narrative
CA$23.72
94.2% undervalued intrinsic discount
Fair Value
Profit Margin
11.48%
Future PE
21.94x
Price in 2031
CA$33.51
US$277
12.5% undervalued intrinsic discount
Fair Value
Profit Margin
12.31%
Future PE
17.56x
Price in 2031
US$425.81
JP¥2.28k
35.7% undervalued intrinsic discount
Fair Value
Revenue
19.16% p.a.
Profit Margin
11.6%
Future PE
16.55x
Price in 2031
JP¥3.17k